- •Assessment of genetic risk is not widely available in middle-income countries.
- •It is crucial to select those patients who will benefit the most from genetic testing.
- •BOADICEA (threshold ≥10%) performed better than other algorithms in this population.
- •Using algorithms to select patients can reduce the number of tests by more than 70%.
- •However, a quarter of all mutation carriers would be missed.
Main outcome measures
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
MS/INCA/Estimativa de Câncer no Brasil, 2016. Available at: http://www.inca.gov.br/wcm/dncc/2015/por-sexo.asp. Accessed 17 December 2015.
- Selecting patients with ovarian cancer for germline BRCA mutation testing: findings from guidelines and a systematic literature review.Adv. Ther. 2016; 33: 129-150
- Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.Am. J. Hum. Genet. 2003; 72: 1117-1130
- Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age.Breast Cancer Res. Treat. 2010; 124: 643-651
- Screening for ovarian cancer.Cancer Control. 2011; 8: 16-21
- Support of the ‘fallopian tube hypothesis' in a prospective series of risk-reducing salpingo-oophorectomy specimens.Eur. J. Cancer. 2013; 49: 132-141
- Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers.J. Natl. Cancer Inst. 2009; 101: 80-87
- PARP inhibitors in ovarian cancer: clinical evidence for informed treatment decisions.Br. J. Cancer. 2015; 113: S10-S16
- Guidelines Version 2.2015 Genetic/Familial High Risk Assessment: Breast and Ovarian.2015 (Accessed December/18, 2015. Available at:)
- Germline mutations in BRCA1 and BRCA2 in epithelial ovarian cancer patients in Brazil.BMC Cancer. 2016; 16: 934
- The BOADICEA model of genetic susceptibility to breast and ovarian cancer.Br. J. Cancer. 2004; 91: 1580-1590
- Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10, 000 individuals.J. Clin. Oncol. 2002; 20: 1480-1490
- Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2.Am. J. Hum. Genet. 1998; 2: 145-158
- A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO.J. Med. Genet. 2004; 41: 474-480
- Association of family risk and lifestyle/comorbidities in ovarian cancer patients.Rev. Assoc. Med. Bras. 2015; 61: 234-239
© 2013 Centre for Cancer Genetic Epidemiology. BOADICEA risk estimation. Available at: https://pluto.srl.cam.ac.uk/cgi-bin/bd3/v3/bd.cgi. Accessed January, 2016.
K. Hughes Hughes, Risk Apps Express Entry. Available at: http://188.8.131.52/HRAExpressEntry/(S(ydr4eggiiob13dr041n54qdc))/default.aspx. Accessed April, 2016.
- The spectrum of BRCA1 and BRCA2 alleles in Latin America and the Caribbean: a clinical perspective, Breast Cancer Res.Treat. 2015; 154: 441-453
- Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics.J. Med. Genet. 2008; 45: 425-431
- Selecting a BRCA risk assessment model for use in a familial cancer clinic.BMC Med. Genet. 2008; 9: 116
- Evaluation of BRCA1 and BRCA2 mutations and risk-prediction models in a typical Asian country (Malaysia) with a relatively low incidence of breast cancer.Breast Cancer Res. 2008; 10: R59
- Limited family structure and BRCA gene mutation status in single cases of breast cancer.JAMA. 2007; 97: 2587-2595
- BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group.J. Clin. Oncol. 2012; 30: 2654-2663
- Dissimilarity between sporadic, non-BRCA1/2 families and hereditary breast cancer, linked to BRCA genes, in the Tunisian population.Breast Cancer. 2015; 23: 807-812
- Association of BRCA1/2 mutations with FMR1 genotypes: effects on menarcheal and menopausal age.Maturitas. 2013; 5: 148-151
- Clinicopathologic characteristics of breast cancer in BRCA-carriers and non-carriers in women 35 years of age or less.Breast. 2014; 3: 770-774
- Genetics of age at menarche: a systematic review.Hum. Reprod. Update. 2012; 18: 198-210
- Clinicopathologic features of BRCA-linked and sporadic ovarian cancer.JAMA. 2000; 83: 2260-2265
- Genetic services and testing in Brazil.J. Commun. Genet. 2013; 4: 355-375
- Costs of genetic testing: supporting Brazilian Public Policies for the incorporating of molecular diagnostic technologies.Genet. Mol. Biol. 2015; 38: 332-337